Table 1 Participants’ demographics and clinical characteristics.

From: Fronto-striato-thalamic circuit connectivity and neuromelanin in schizophrenia: an fMRI and neuromelanin-MRI study

 

HCs (n = 63)

SCZ (n = 29)

t or X2

p

Age (years)a

24.13 (3.70)

25.55 (4.43)

−1.61

0.110

Sex (male/female)

30/33

14/15

0.00

0.953

Handedness (right/left)

56/7

24/4

0.18

0.668

IQa

127.55 (7.77)

102.64 (17.58)

6.91

<0.001*

DOI (months)a

 

73.52 (46.70)

  

PANSSa

 Positive symptoms

 

11.48 (3.09)

  

 Negative symptoms

 

13.33 (4.59)

  

 General symptoms

 

24.04 (4.70)

  

GAFa

 

56.37 (13.87)

  

HAMAa

 

2.96 (2.41)

  

HAMDa

 

3.96 (2.95)

  

Antipsychotic doseb

 

13.65 (8.96)

  
  1. HCs healthy controls, SCZ schizophrenia patients, IQ intelligence quotient, DOI duration of illness, PANSS Positive and Negative Syndrome Scale, GAF Global Assessment of Functioning, HAMA Hamilton Rating Scale for Anxiety, HAMD Hamilton Rating Scale for Depression.
  2. aThe values are presented as the mean (standard deviation).
  3. bMean daily olanzapine equivalent of antipsychotics. (*) indicates significance at p < 0.05.
Back to article page